[go: up one dir, main page]

CY1120098T1 - Συνθεσεις που περιεχουν βορτιοξετινη και δονεπεζιλη - Google Patents

Συνθεσεις που περιεχουν βορτιοξετινη και δονεπεζιλη

Info

Publication number
CY1120098T1
CY1120098T1 CY20181100347T CY181100347T CY1120098T1 CY 1120098 T1 CY1120098 T1 CY 1120098T1 CY 20181100347 T CY20181100347 T CY 20181100347T CY 181100347 T CY181100347 T CY 181100347T CY 1120098 T1 CY1120098 T1 CY 1120098T1
Authority
CY
Cyprus
Prior art keywords
compositions containing
bortioxetine
gones
vortexetine
donepezil
Prior art date
Application number
CY20181100347T
Other languages
English (en)
Inventor
Connie Sanchez Morillo
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of CY1120098T1 publication Critical patent/CY1120098T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Φαρμακευτικές συνθέσεις που περιέχουν βορτιοξετίνη και δονεπεζίλη παρέχονται και η χρήση μιας τέτοιας σύνθεσης για τη θεραπεία της γνωστικής δυσλειτουργίας.
CY20181100347T 2012-12-13 2018-03-27 Συνθεσεις που περιεχουν βορτιοξετινη και δονεπεζιλη CY1120098T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261736799P 2012-12-13 2012-12-13
PCT/EP2013/076337 WO2014090929A1 (en) 2012-12-13 2013-12-12 Compositions comprising vortioxetine and donepezil

Publications (1)

Publication Number Publication Date
CY1120098T1 true CY1120098T1 (el) 2018-12-12

Family

ID=49943326

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100347T CY1120098T1 (el) 2012-12-13 2018-03-27 Συνθεσεις που περιεχουν βορτιοξετινη και δονεπεζιλη

Country Status (44)

Country Link
US (1) US9211288B2 (el)
EP (1) EP2931276B1 (el)
JP (1) JP6257641B2 (el)
KR (1) KR102171152B1 (el)
CN (1) CN104853755B (el)
AP (1) AP2015008498A0 (el)
AR (2) AR093939A1 (el)
AU (1) AU2013357308B2 (el)
BR (1) BR112015013675B1 (el)
CA (1) CA2893468C (el)
CL (1) CL2015001615A1 (el)
CR (1) CR20150303A (el)
CY (1) CY1120098T1 (el)
DK (1) DK2931276T3 (el)
DO (1) DOP2015000133A (el)
EA (1) EA028300B1 (el)
EC (1) ECSP15023182A (el)
ES (1) ES2663680T3 (el)
GE (1) GEP201706739B (el)
GT (1) GT201500143A (el)
HR (1) HRP20180333T1 (el)
HU (1) HUE036280T2 (el)
IL (1) IL239192B (el)
LT (1) LT2931276T (el)
MA (1) MA38253B1 (el)
ME (1) ME03029B (el)
MX (1) MX362886B (el)
MY (1) MY171802A (el)
NI (1) NI201500078A (el)
NO (1) NO2970700T3 (el)
NZ (1) NZ708595A (el)
PE (1) PE20151026A1 (el)
PH (1) PH12015501302B1 (el)
PL (1) PL2931276T3 (el)
PT (1) PT2931276T (el)
RS (1) RS56949B1 (el)
RU (1) RU2635528C2 (el)
SG (1) SG11201504483YA (el)
SI (1) SI2931276T1 (el)
SM (1) SMT201800135T1 (el)
TN (1) TN2015000235A1 (el)
UA (1) UA114016C2 (el)
WO (1) WO2014090929A1 (el)
ZA (1) ZA201504274B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105218482B (zh) * 2014-06-24 2018-04-06 杭州和泽医药科技有限公司 沃替西汀氢溴酸盐β晶型的制备方法
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
CN105315184B (zh) * 2015-06-26 2017-03-29 上海医药工业研究院 一种沃替西汀的制备方法及其中间体
EP3324952B1 (en) * 2015-07-17 2020-12-16 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
CN105534933A (zh) * 2016-01-19 2016-05-04 美吉斯制药（厦门）有限公司 一种沃替西汀口腔崩解片及其制备方法
US9820984B1 (en) 2016-07-01 2017-11-21 H. Lundbeck A/S Dosing regimens for fast onset of antidepressant effect
US10398691B2 (en) 2017-03-30 2019-09-03 Rundle Research, LLC Methods of treating depression
US20180280381A1 (en) 2017-03-30 2018-10-04 Rundle Research, LLC Methods of treating depression
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK569087A (da) 1986-10-31 1988-05-01 Sumitomo Pharma Quinolin-derivater, deres fremstilling og anvendelse
IT1225462B (it) 1987-04-03 1990-11-14 Mediolanum Farmaceutici Srl Sali organici di derivati della fisostigmina
ATE411026T1 (de) 1987-05-04 2008-10-15 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
EP0403713A1 (en) 1989-06-22 1990-12-27 Merrell Dow Pharmaceuticals Inc. Novel acetylcholinesterase inhibitors
US4914102A (en) 1989-09-28 1990-04-03 Hoechst Roussel Pharmaceuticals, Inc. N-aminocarbamates related to physostigmine, pharmacentical compositions and use
TW200462B (el) 1990-09-27 1993-02-21 Hoechst Roussel Pharma
US5246947A (en) 1991-09-23 1993-09-21 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression
US5231093A (en) 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
ES2042384B1 (es) 1991-12-26 1994-06-01 Boehringer Ingelheim Espana Procedimiento para obtener derivados bis-piridinicos.
SE9302080D0 (sv) 1993-06-16 1993-06-16 Ab Astra New compounds
DE69707659T2 (de) 1996-04-12 2002-05-08 Aventis Pharmaceuticals Inc., Bridgewater Isatinderivate als acetylcholinesterase-inhibitoren und analgetika
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
JP4405811B2 (ja) 2002-03-29 2010-01-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 （１−インダノン）−（１，２，３，６−テトラヒドロピリジン）誘導体
WO2003101458A1 (en) * 2002-05-31 2003-12-11 H. Lundbeck A/S A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
JP2006512417A (ja) * 2002-12-24 2006-04-13 ニューロケム （インターナショナル） リミテッド β−アミロイド関連疾患の治療のための治療用製剤
KR20090009951A (ko) * 2006-05-08 2009-01-23 데이고꾸세이약꾸가부시끼가이샤 항치매제를 포함하는 경피 흡수 제제
US20080032965A1 (en) * 2006-06-09 2008-02-07 Hirst Warren D Method for enhancing cognitive function
US8722684B2 (en) 2006-06-16 2014-05-13 H. Lundbeck A/S 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
WO2009005519A1 (en) * 2007-06-29 2009-01-08 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW201033181A (en) 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Also Published As

Publication number Publication date
MX362886B (es) 2019-02-22
US20150297585A1 (en) 2015-10-22
AP2015008498A0 (en) 2015-05-31
SMT201800135T1 (it) 2018-05-02
KR102171152B1 (ko) 2020-10-29
MA38253A1 (fr) 2017-02-28
NO2970700T3 (el) 2018-05-26
RS56949B1 (sr) 2018-05-31
BR112015013675A2 (pt) 2017-07-11
ME03029B (me) 2018-10-20
IL239192A0 (en) 2015-07-30
EP2931276A1 (en) 2015-10-21
ECSP15023182A (es) 2015-12-31
GEP201706739B (en) 2017-09-25
IL239192B (en) 2019-03-31
AU2013357308A1 (en) 2015-06-18
RU2635528C2 (ru) 2017-11-13
MX2015007269A (es) 2015-08-12
GT201500143A (es) 2016-01-22
CA2893468C (en) 2021-01-12
JP2016502990A (ja) 2016-02-01
MA38253B1 (fr) 2017-10-31
SG11201504483YA (en) 2015-07-30
PH12015501302A1 (en) 2016-02-01
KR20150095681A (ko) 2015-08-21
EA028300B1 (ru) 2017-10-31
AU2013357308B2 (en) 2017-08-31
EA201590932A1 (ru) 2015-10-30
CL2015001615A1 (es) 2015-08-07
BR112015013675B1 (pt) 2022-04-26
DOP2015000133A (es) 2015-11-30
SI2931276T1 (en) 2018-05-31
ES2663680T3 (es) 2018-04-16
US9211288B2 (en) 2015-12-15
PE20151026A1 (es) 2015-07-11
EP2931276B1 (en) 2018-02-21
CA2893468A1 (en) 2014-06-19
PT2931276T (pt) 2018-03-19
CR20150303A (es) 2016-07-07
TN2015000235A1 (en) 2016-10-03
WO2014090929A1 (en) 2014-06-19
HK1212601A1 (en) 2016-06-17
HRP20180333T1 (hr) 2018-04-06
HUE036280T2 (hu) 2018-06-28
AR093939A1 (es) 2015-07-01
NZ708595A (en) 2019-06-28
JP6257641B2 (ja) 2018-01-10
CN104853755B (zh) 2017-08-22
LT2931276T (lt) 2018-04-10
PL2931276T3 (pl) 2018-06-29
NI201500078A (es) 2016-02-15
AR125920A2 (es) 2023-08-23
MY171802A (en) 2019-10-30
UA114016C2 (xx) 2017-04-10
PH12015501302B1 (en) 2016-02-01
CN104853755A (zh) 2015-08-19
DK2931276T3 (en) 2018-03-26
ZA201504274B (en) 2016-11-30
RU2015122256A (ru) 2017-01-16

Similar Documents

Publication Publication Date Title
CY1120098T1 (el) Συνθεσεις που περιεχουν βορτιοξετινη και δονεπεζιλη
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1120529T1 (el) Προφαρμακα φουμαρικων αλατων και η χρηση τους στην αγωγη ποικιλων νοσων
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
CL2015000942A1 (es) Compuestos de benceno sustituido.
EP3480211A4 (en) HANP FC CONTAINING MOLECULAR CONJUGATE
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
MX378273B (es) Compuestos activos hacia bromodominios.
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
UY34395A (es) ?Tratamiento de Esclerosis Múltiple con la Combinación de Laquinimod y Fingolimod?.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EP3040355A4 (en) ASPHALT MODIFYING AGENT AND ASPHALT COMPOSITION THEREWITH
CL2015002897A1 (es) Inhibidores de bace1
CY1122313T1 (el) Ορβεπιταντη για την αγωγη του χρονιου κνησμου
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
DK3554534T3 (da) Farmaceutisk sammensætning omfattende insulin
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
EP3326675A4 (en) NEEDLE UNIT
MX384131B (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y métodos.